Food and Drug Administration for licensing the first of the two new Thousand Oaks facilities. The two new Thousand Oaks manufacturing facilities will add 150 employees by 2001, bringing Baxter's total employee base at that site to approximately 500.īaxter has already submitted its application to the U.S. 'We will be able to better leverage our manufacturing capabilities and continue to deliver innovative products to patients around the world,' Glanzmann added.Īs with the first operation built on the site, the new Thousand Oaks facility will manufacture Baxter's recombinant Factor VIII therapy, Recombinate Antihemophilic Factor, a genetically modified clotting factor used as a therapy for people with hemophilia. Jansen Kraemer Jr., chairman and chief executive officer of Deerfield, Ill.-based Baxter International ( Added Thomas Glanzmann, president of Baxter's Glendale, Calif.-based Hyland Immuno business, 'The significant investment in Hyland Immuno facilities positions us to maximize our broad biopharmaceutical technology platforms, and is a clear commitment to manufacturing excellence and continued regulatory compliance. 'This investment reflects the tremendous opportunity we see for growth in the biosciences area,' said Harry M. All told, Hyland Immuno's worldwide expansions that are either planned, under way or recently completed total a whopping $400 million in capital investment. Together, the two expansions entail a capital investment of $100 million.Īt the same time, Baxter's Hyland Immuno unit is rapidly expanding in Switzerland and Austria, reflecting the inherent growth imperative in the burgeoning biotechnology business. Baxter is planning a second and third manufacturing suite at the Thousand Oaks site. The latest expansive move for Baxter's Hyland Immuno unit - which develops and produces therapeutic proteins to treat hemophilia, immune deficiencies and other blood-related disorders - is unfolding in Thousand Oaks, Calif. Of Baxter's $400 Million Global Biotech PushĮxpansion, you might say, is in the blood of the Hyland Immuno Division of Baxter Healthcare - to the tune of US$400 million, in fact.

New $100 Million California Plant Part of Baxter's $400 Million Global Biotech Push - Site Selection Online Insiderįrom Site Selection's exclusive New Plant database

Stephen baxter manifold trilogy